Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch

Nuvation Bio Inc. (NYSE:NUVB) is 1 of the best debased outgo stocks to bargain nether $5. On March 2, Nuvation Bio (NUVB) reported a pivotal 2025 marked by the FDA support and accelerated commercialized motorboat of Ibtrozi (Taletrectinib) for ROS1-positive non-small compartment lung cancer. With 432 caller diligent starts by year-end, the drug’s uptake outpaced anterior people competitors by sixfold. Financially, the institution reported $41.9 cardinal successful Q4 revenue, supported by a beardown currency presumption of $529.2 cardinal pursuing planetary partnerships with Eisai and Nippon Kayaku.

While aboriginal gross was impacted by a precocious measurement of late-line patients with shorter attraction durations, absorption expects gross stableness to amended arsenic first-line diligent penetration increases done 2026. The institution is emphasizing Ibtrozi’s differentiated objective profile, specifically its 50-month median duration of effect successful TKI-naive patients and its favorable information profile. The CEO highlighted the drug’s unsocial measured inhibition of TRKB, which supports intracranial illness power portion avoiding the terrible neurological toxicities seen successful different therapies.

To grow the drug’s reach, Nuvation Bio has initiated the TRUST-4 Phase 3 survey successful the adjuvant setting, targeting early-stage patients who necessitate precocious tolerability for semipermanent adherence. Beyond Ibtrozi, Nuvation Bio Inc. (NYSE:NUVB) is advancing its 2nd pb program, safusidenib, for IDH1-mutant glioma. The institution precocious launched the Phase 3 SIGMA proceedings for high-grade patients, who presently person nary approved targeted options, with a projected readout successful 2029. Additionally, a smaller Phase 2 cohort for people 3 oligodendroglioma is underway with results expected by 2027, perchance offering an accelerated support pathway.

Copyright: epstock / 123RF Stock Photo

Nuvation Bio Inc. (NYSE:NUVB) is simply a clinical-stage biopharmaceutical institution that develops therapeutic candidates for oncology. Its pb merchandise campaigner is taletrectinib, which is an ROS1 inhibitor for the attraction of patients with ROS1+ non-small compartment lung cancer.

While we admit the imaginable of NUVB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Most Promising Micro-Cap Stocks According to Analysts.

Disclosure: None. Follow Insider Monkey connected Google News.